Need an investment idea? Check out Popular Stocks and S2O Stock Screener.

Market Price

12.77 

0.00 0.0%

as of Sep 29 '22

52 Week Range:

12.77 17.95


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. The company has a strategic collaboration and license agreement with Minovia Therapeutics Ltd. for the research, development, and commercialization of cell therapy programs for diseases caused by mitochondrial dysfunction. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19 Mar '20 Mar '21 Mar '22
Equity (BVPS) 5.16
4.94
5.05
5.22
5.54
5.69
6.47
6.19
6.56
6.70
growth rate -4.3% 2.2% 3.4% 6.1% 2.7% 13.7% -4.3% 6.0% 2.1%
Earnings BIT 1,169.04
1,146.96
183,094.00
226,873.00
269,502.00
273,814.00
271,818.00
282,416.00
267,483.00
250,932.00
218,145.00
growth rate -1.9% 15,863.4% 23.9% 18.8% 1.6% -0.7% 3.9% -5.3% -6.2% -13.1%
Avg.PE 19.96
28.33
37.17
28.90
18.79
13.48
17.44
16.85
20.40
19.40
27.64
growth rate 41.9% 31.2% -22.3% -35.0% -28.3% 29.4% -3.4% 21.1% -4.9% 42.5%
ROA 5.72
5.82
5.87
7.88
10.78
12.08
8.95
11.84
9.27
5.25
growth rate 1.8% 0.9% 34.2% 36.8% 12.1% -25.9% 32.3% -21.7% -43.4%
ROE 7.67
7.97
7.80
10.51
15.03
17.28
12.97
17.59
15.34
9.02
growth rate 3.9% -2.1% 34.7% 43.0% 15.0% -24.9% 35.6% -12.8% -41.2%
ROIC 7.61
7.94
7.47
10.28
14.30
16.00
12.68
17.24
15.26
8.44
growth rate 4.3% -5.9% 37.6% 39.1% 11.9% -20.8% 36.0% -11.5% -44.7%
Cur. Ratio 2.49
2.64
2.68
2.29
2.17
2.19
2.01
1.72
1.09
1.47
growth rate 6.0% 1.5% -14.6% -5.2% 0.9% -8.2% -14.4% -36.6% 34.9%
Quick Ratio 1.79
1.91
2.23
1.88
1.70
1.66
1.58
1.32
0.84
1.14
growth rate 6.7% 16.8% -15.7% -9.6% -2.4% -4.8% -16.5% -36.4% 35.7%
Leverage 1.38
1.36
1.30
1.36
1.43
1.43
1.47
1.51
1.80
1.64
growth rate -1.5% -4.4% 4.6% 5.2% 0.0% 2.8% 2.7% 19.2% -8.9%
Balance Sheet Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19 Mar '20 Mar '21 Mar '22
Acct.Receivable 261,800.00
300,121.00
335,349.00
339,841.00
344,002.00
320,803.00
327,924.00
362,741.00
370,598.00
357,162.00
404,001.00
growth rate 14.6% 11.7% 1.3% 1.2% -6.7% 2.2% 10.6% 2.2% -3.6% 13.1%
Acct.Payable 178,439.00
187,032.00
226,602.00
181,559.00
182,826.00
140,909.00
185,280.00
171,954.00
124,777.00
130,739.00
growth rate 4.8% 21.2% -19.9% 0.7% -22.9% 31.5% -7.2% -27.4% 4.8%
Cur.Assets 7,967.00
827,190.00
913,292.00
965,958.00
897,537.00
876,665.00
845,619.00
857,159.00
867,514.00
872,588.00
923,354.00
growth rate 10,282.7% 10.4% 5.8% -7.1% -2.3% -3.5% 1.4% 1.2% 0.6% 5.8%
Total Assets 12,885.79
1,445,561.00
1,653,108.00
1,793,578.00
1,799,338.00
1,820,901.00
1,858,205.00
1,897,648.00
2,318,160.00
2,273,628.00
2,332,395.00
growth rate 11,118.3% 14.4% 8.5% 0.3% 1.2% 2.1% 2.1% 22.2% -1.9% 2.6%
Cash 1,941.07
264,912.00
391,374.00
396,430.00
360,030.00
340,923.00
331,731.00
311,074.00
318,391.00
326,128.00
315,986.00
growth rate 13,547.7% 47.7% 1.3% -9.2% -5.3% -2.7% -6.2% 2.4% 2.4% -3.1%
Inventory 1,140.57
128,180.00
135,228.00
156,907.00
161,691.00
182,537.00
147,626.00
151,511.00
151,017.00
164,080.00
153,072.00
growth rate 11,138.2% 5.5% 16.0% 3.1% 12.9% -19.1% 2.6% -0.3% 8.7% -6.7%
Cur.Liabilities 3,204.53
313,536.00
340,688.00
420,890.00
413,359.00
399,856.00
421,620.00
495,759.00
798,708.00
592,372.00
687,411.00
growth rate 9,684.1% 8.7% 23.5% -1.8% -3.3% 5.4% 17.6% 61.1% -25.8% 16.0%
Liabilities 3,519.06
383,535.00
384,632.00
475,662.00
540,129.00
549,091.00
589,916.00
639,252.00
1,028,992.00
887,513.00
872,087.00
growth rate 10,798.8% 0.3% 23.7% 13.6% 1.7% 7.4% 8.4% 61.0% -13.8% -1.7%
LT Debt 0.00
7.30
64.00
90.00
1,599.00
440.00
3,515.00
1,572.00
3,142.00
80,400.00
676.00
growth rate 777.2% 40.6% 1,676.7% -72.5% 698.9% -55.3% 99.9% 2,458.9% -99.2%
Equity 9,366.73
10,806.38
1,268,476.00
1,317,916.00
1,259,209.00
1,271,810.00
1,268,289.00
1,258,396.00
1,289,168.00
1,386,115.00
1,460,308.00
growth rate 15.4% 11,638.2% 3.9% -4.5% 1.0% -0.3% -0.8% 2.5% 7.5% 5.4%
Common Shares 9,237.00
2,874.00
2,250.00
2,212.00
2,161.00
2,112.00
2,033.00
103,001.00
103,001.00
103,001.00
103,001.00
growth rate -68.9% -21.7% -1.7% -2.3% -2.3% -3.7% 4,966.5% 0.0% 0.0% 0.0%
Cash Flow Statement Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19 Mar '20 Mar '21 Mar '22
Capital Expenditures 328.44
31,333.00
29,261.00
24,159.00
33,512.00
29,010.00
25,077.00
25,190.00
41,267.00
31,384.00
30,739.00
growth rate 9,440.0% -6.6% -17.4% 38.7% -13.4% -13.6% 0.5% 63.8% -24.0% -2.1%
Cash Dividends 531.11
552.47
58,656.00
62,146.00
69,615.00
70,119.00
71,634.00
72,066.00
73,539.00
76,157.00
85,236.00
growth rate 4.0% 10,517.1% 6.0% 12.0% 0.7% 2.2% 0.6% 2.0% 3.6% 11.9%
Cash From OA 1,588.61
144,153.00
214,257.00
187,686.00
313,737.00
235,612.00
312,614.00
258,630.00
221,998.00
306,843.00
257,444.00
growth rate 8,974.2% 48.6% -12.4% 67.2% -24.9% 32.7% -17.3% -14.2% 38.2% -16.1%
FCF per Share 0.49
0.26
0.58
0.40
0.39
1.07
1.01
1.18
0.74
0.96
growth rate -46.9% 123.1% -31.0% -2.5% 174.4% -5.6% 16.8% -37.3% 29.7%
FCF 108,548.00
76,607.00
158,111.00
106,520.00
195,620.00
186,964.00
272,329.00
206,502.00
144,110.00
229,402.00
226,705.00
growth rate -29.4% 106.4% -32.6% 83.7% -4.4% 45.7% -24.2% -30.2% 59.2% -1.2%
Income Statement Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19 Mar '20 Mar '21 Mar '22
Sales 8,918.36
1,005,612.00
1,139,909.00
1,247,259.00
1,372,706.00
1,311,665.00
1,300,316.00
1,306,348.00
1,300,843.00
1,249,528.00
1,296,163.00
growth rate 11,175.8% 13.4% 9.4% 10.1% -4.5% -0.9% 0.5% -0.4% -3.9% 3.7%
Op.Income 1,209.97
82,851.00
183,094.00
226,873.00
269,502.00
273,814.00
271,818.00
282,416.00
267,483.00
250,932.00
218,145.00
growth rate 6,747.3% 121.0% 23.9% 18.8% 1.6% -0.7% 3.9% -5.3% -6.2% -13.1%
IBT 1,169.08
1,169.46
121,974.00
189,683.00
261,770.00
281,770.00
218,113.00
248,967.00
245,350.00
145,323.00
156,886.00
growth rate 0.0% 10,330.0% 55.5% 38.0% 7.6% -22.6% 14.2% -1.5% -40.8% 8.0%
Net Income 719.72
82,851.00
90,874.00
135,856.00
193,687.00
218,701.00
164,679.00
222,265.00
195,411.00
120,589.00
124,086.00
growth rate 11,411.6% 9.7% 49.5% 42.6% 12.9% -24.7% 35.0% -12.1% -38.3% 2.9%
EPS 8.46
32.16
40.39
61.40
89.62
103.55
81.02
114.94
104.08
64.90
growth rate 280.1% 25.6% 52.0% 46.0% 15.5% -21.8% 41.9% -9.5% -37.6%
Gross Profit 5,986.94
681,485.00
809,281.00
914,062.00
1,037,110.00
991,162.00
1,006,066.00
1,014,298.00
1,024,104.00
1,003,465.00
1,043,154.00
growth rate 11,282.9% 18.8% 13.0% 13.5% -4.4% 1.5% 0.8% 1.0% -2.0% 4.0%
R&D 1,463.66
191,460.00
206,594.00
225,665.00
208,129.00
220,781.00
208,682.00
224,226.00
224,489.00
246,010.00
growth rate 12,980.9% 7.9% 9.2% -7.8% 6.1% -5.5% 7.5% 0.1% 9.6%

Quarterly Statements

Item Name Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Earnings BIT 91,197.00
35,797.00
54,064.00
53,347.00
74,937.00
growth rate -60.8% 51.0% -1.3% 40.5%
Balance Sheet Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Acct.Receivable 357,162.00
381,528.00
375,370.00
390,722.00
404,001.00
growth rate 6.8% -1.6% 4.1% 3.4%
Acct.Payable 124,777.00
108,453.00
111,568.00
136,892.00
130,739.00
growth rate -13.1% 2.9% 22.7% -4.5%
Cur.Assets 872,588.00
868,715.00
876,454.00
939,331.00
923,354.00
growth rate -0.4% 0.9% 7.2% -1.7%
Total Assets 2,273,628.00
2,249,456.00
2,261,508.00
2,356,245.00
2,332,395.00
growth rate -1.1% 0.5% 4.2% -1.0%
Cash 326,128.00
301,920.00
318,295.00
350,213.00
315,986.00
growth rate -7.4% 5.4% 10.0% -9.8%
Inventory 164,080.00
157,254.00
148,732.00
151,576.00
153,072.00
growth rate -4.2% -5.4% 1.9% 1.0%
Cur.Liabilities 592,372.00
581,580.00
554,768.00
597,976.00
687,411.00
growth rate -1.8% -4.6% 7.8% 15.0%
Liabilities 887,513.00
866,587.00
843,886.00
889,954.00
872,087.00
growth rate -2.4% -2.6% 5.5% -2.0%
LT Debt 80,400.00
308.00
444.00
664.00
676.00
growth rate -99.6% 44.2% 49.6% 1.8%
Equity 1,386,115.00
1,382,869.00
1,417,622.00
1,466,291.00
1,460,308.00
growth rate -0.2% 2.5% 3.4% -0.4%
Common Shares 103,001.00
103,001.00
103,001.00
103,001.00
103,001.00
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Capital Expenditures 8,469.00
9,352.00
8,141.00
2,746.00
10,500.00
growth rate 10.4% -13.0% -66.3% 282.4%
Cash Dividends 38,914.00
38,914.00
46,322.00
46,322.00
growth rate 0.0% 19.0% 0.0%
Cash From OA 81,700.00
40,083.00
99,302.00
69,474.00
48,585.00
growth rate -50.9% 147.7% -30.0% -30.1%
FCF 73,231.00
30,731.00
91,161.00
66,728.00
38,085.00
growth rate -58.0% 196.6% -26.8% -42.9%
Income Statement Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Sales 308,621.00
326,143.00
325,523.00
340,627.00
303,870.00
growth rate 5.7% -0.2% 4.6% -10.8%
Op.Income 91,197.00
35,797.00
54,064.00
53,347.00
74,937.00
growth rate -60.8% 51.0% -1.3% 40.5%
IBT -18,904.00
35,831.00
53,255.00
78,316.00
-10,517.00
growth rate 100.0% 48.6% 47.1% -100.0%
Net Income -12,328.00
30,687.00
40,922.00
60,885.00
-8,409.00
growth rate 100.0% 33.4% 48.8% -100.0%
EPS
growth rate
Gross Profit 250,294.00
263,912.00
263,019.00
271,268.00
244,955.00
growth rate 5.4% -0.3% 3.1% -9.7%
R&D 55,668.00
58,313.00
60,747.00
58,588.00
68,362.00
growth rate 4.8% 4.2% -3.6% 16.7%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

E (26.81)

YOY Growth Grade:

E (29.75)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 23.96 21.46 20.20
EPS / Growth 0.0% 0.60 10.3%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 16.7%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 0.0% 9.0% 9.0%
Future PE 0.00 20.73 20.73
Future EPS 0.60 1.41 1.41
Value Price
MOS %
0.00
-100.0%
7.22
-43.4%
7.22
-43.4%
MOS Price 0.00 3.61 3.61
IRT 21.46 11.82 11.82

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.